Skip to main content

Table 4 Changes in Fasting Lipid Profile from Baseline to Week 12

From: Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients

   Baseline Week 12 Baseline to week 12
  Lipid Lowering Therapy Mean (SD) Mean (SD) Mean Change SD P-value
Total Cholesterol No (n = 44) 183 (36.6) 180 (35.4) -9.2 23.2 0.02
  Yes (n = 18) 225 (64.3) 221 (55.1) -2.9 44.3 0.80
  Total population 195 (49.7) 191 (45.1) -7.3 30.7 0.09
Triglycerides No (n = 38) 178 (114) 153 (105) -33.1 86.3 0.04
  Yes (n = 16) 411 (392) 303 (281) -81.2 348.3 0.40
  Total population 246 (253) 194 (182) -47.4 199.9 0.11
HDL No (n = 37) 45.3 (11.6) 44.6 (13.7) -4.5 9.4 0.01
  Yes (n = 17) 36.1 (15.5) 39.1 (17.2) 1.7 9.5 0.49
  Total population 42.4 (13.5) 43.0 (14.8) -2.5 9.8 0.88
LDL No (n = 38) 106 (28.0) 105 (25.9) -4.2 21.8 0.28
  Yes (n = 16) 127 (54.9) 125 (36.1) 3.6 48.6 0.79
  Total population 112 (38.7) 110 (30.2) -1.9 31.8 0.69
  1. HDL = high density lipoprotein; LDL = low density lipoprotein; SD = standard deviation